This page uses content from Wikipedia and is licensed under CC BY-SA.
Esmirtazapine Clinical data Routes of administration Oral ATC code Legal status Legal status
Pharmacokinetic data Metabolism Liver ( CYP2D6)  Identifiers
( S)-1,2,3,4,10,14b-hexahydro-2-methylpyrazino(2,1-a)pyrido(2,3-c)(2)benzazepine CAS Number PubChem CID DrugBank ChemSpider UNII KEGG ECHA InfoCard 100.056.994 Chemical and physical data Formula C 17 H 19 N 3 Molar mass 265.35 g/mol g·mol −1 3D model ( JSmol) Melting point 114 to 116 °C (237 to 241 °F) Solubility in water Soluble in methanol and chloroform mg/mL (20 °C)
(what is this?) (verify)
Esmirtazapine ( ORG-50,081) is a drug which was under development by Organon for the treatment of insomnia and vasomotor symptoms (e.g., hot flashes) associated with menopause.    Esmirtazapine is the (  S)-(+)- enantiomer of mirtazapine and possesses similar overall pharmacology, including inverse agonist actions at H and 1 5-HT and 2 receptors antagonist actions at α. 2-adrenergic receptors  As of March 2010, Merck terminated internal clinical development program for esmirtazapine, for hot flashes and insomnia, for strategic reasons.